Articles 19(1), 20(1) and 23(1): The Core Obligations Framework

1. Key takeaways

The Ethiopian Food and Drug Administration Proclamation No. 1112/2019 builds the skeleton of medical device regulation on three core provisions. Article 19(1) establishes the proportionality principle: regulatory intensity must be commensurate with the type, nature and potential risk of the product. Article 20(1) establishes the product obligation: any medical device manufactured, imported, exported, stored, distributed, transported, sold, held, used or transferred to another person in the country must be registered and obtain marketing authorization. Article 23(1) establishes the establishment obligation: no medical device establishment may engage in device trade without being registered and licensed. The three provisions answer three distinct questions — how strongly to regulate, what applies to products, and what applies to establishments — and together they frame every compliance conversation a company will have in Ethiopia. Reading them as an integrated scheme, rather than as isolated clauses, is what allows a manufacturer to place each operational activity, from warehousing to distribution contracts, on a firm legal footing and to identify precisely which registrations, licences and dossiers the activity presupposes.

2. Legal basis

3. Expert insights

Insight 1: the chain of regulated activities in Article 20(1) is extremely long and covers nearly every commercial step. Manufacturing, import, export, storage, distribution, transport, sale, holding, use and transfer — all ten activities are brought within the obligation. This means that marketing authorization is required not only at the point of sale: mere holding, transport and transfer are equally regulated. Logistics and warehousing service providers therefore cannot argue that they only move goods and that registration does not concern them; their activities fall squarely within the statutory language.

Insight 2: Article 20(4) formulates the conditions of registration as cumulative requirements. A device may be registered only where the manufacturer complies with good manufacturing practice (GMP), where the dossier has been assessed as satisfying safety, quality and efficacy (or performance), and where laboratory quality testing requirements are met as appropriate. The three elements are cumulative, not alternative — a GMP certificate cannot substitute for the dossier, and a passing dossier cannot excuse laboratory testing where the authority requires it. Planning submissions on the assumption that one element can compensate for a weak other element is a structural error.

Insight 3: Article 19(1) is the legal basis for every differentiated regulatory measure. Classification, the low-risk notification procedure, the SRA reliance route and the allocation of review resources by class all derive their legitimacy from this proportionality provision. When seeking a simplified pathway, citing Article 19(1) is more persuasive than citing a guideline alone, because it anchors the request in statute and obliges the authority to respond within its own legal logic.

Insight 4: product obligations and establishment obligations are independent and cannot substitute for each other. Article 20(1) addresses products; Article 23(1) addresses establishments. A company holding a Certificate of Competence that sells a device without marketing authorization is still acting unlawfully; conversely, a device with a valid marketing authorization imported by an unlicensed establishment is equally unlawful. Both certificates must be in place simultaneously for any commercial act to be complete and legal, which is why compliance monitoring must run on two parallel ledgers.

Insight 5: Article 21(1) brings changes onto a mandatory track. Where a change is introduced that affects the safety, quality or efficacy of a registered device, the device must not be placed on the market unless the registrant notifies the change and obtains the authority’s approval. This elevates changes from after-the-fact reporting to prior approval, a position markedly stricter than some other markets. Change control procedures must therefore include a formal gate that halts implementation until approval is documented.

4. Practical recommendations

1. Bring all ten regulated activities into the compliance inventory, paying particular attention to warehousing and transport steps.
2. Prepare GMP, dossier and testing in parallel under the three cumulative conditions: do not wait for them serially.
3. Cite Article 19(1) when seeking simplified pathways, grounding the argument in the proportionality principle.
4. Maintain separate ledgers for product certificates and establishment certificates to avoid the substitution misjudgment.
5. Determine whether prior approval is needed before implementing any change: never change first and notify afterwards.
6. Allocate responsibilities under the three provisions in the agency agreement, clarifying the boundary of each party’s obligations.

5. Verification checklist

• □ Confirmed that the products to be marketed hold, or are under application for, marketing authorization (Article 20(1))
• □ Confirmed coverage of the three cumulative conditions of GMP, dossier and testing (Article 20(4))
• □ Confirmed that the operating establishment holds a Certificate of Competence (Article 23(1))
• □ Prepared an Article 19(1) proportionality rationale for any simplified pathway sought
• □ Established a prior-approval determination process for changes (Article 21(1))

Regulatory information verified as of October 29, 2026. The article numbers and contents set out above are based on the current official text of Proclamation No. 1112/2019; where the law is amended, the information must be re-checked.

• Ethiopia local support: GRZAN assists manufacturers from the Chinese mainland and overseas in dealing with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical dossier preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility assessment, Essential Principles conformity justification, labelling and instructions-for-use localization in English, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.